BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8928103)

  • 1. [Mycophenolate mofetil--a new immunosuppressive agent].
    Bergan S; Albrechtsen D; Fauchald P
    Tidsskr Nor Laegeforen; 1996 Aug; 116(20):2439-41. PubMed ID: 8928103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil: a unique immunosuppressive agent.
    Hood KA; Zarembski DG
    Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
    Simmons WD; Rayhill SC; Sollinger HW
    Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
    Behrend M
    Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil.
    Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
    Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualization of mycophenolate mofetil dose in renal transplant recipients.
    van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
    Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.
    Kirklin JK; Bourge RC; Naftel DC; Morrow WR; Deierhoi MH; Kauffman RS; White-Williams C; Nomberg RI; Holman WL; Smith DC
    J Heart Lung Transplant; 1994; 13(3):444-50. PubMed ID: 8061021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation.
    Bardsley-Elliot A; Noble S; Foster RH
    BioDrugs; 1999 Nov; 12(5):363-410. PubMed ID: 18031189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of mycophenolate mofetil in clinical renal transplantation.
    Hodge EE
    World J Urol; 1996; 14(4):249-55. PubMed ID: 8873440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation.
    Young M; Plosker GL
    Pharmacoeconomics; 2002; 20(10):675-713. PubMed ID: 12162756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
    Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
    Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
    Allison AC; Eugui EM
    Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.
    Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA
    Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mycophenolate mofetil, a new immunosuppressive agent. Is pharmacokinetic monitoring justified?].
    Barré J; Simon N; Tillement JP
    Therapie; 1997; 52(2):139-42. PubMed ID: 9231509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil: a dermatologic perspective.
    Mydlarski PR
    Skin Therapy Lett; 2005 Apr; 10(3):1-6. PubMed ID: 15986076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of mycophenolate mofetil.
    Ransom JT
    Ther Drug Monit; 1995 Dec; 17(6):681-4. PubMed ID: 8588241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.
    Taylor DO; Ensley RD; Olsen SL; Dunn D; Renlund DG
    J Heart Lung Transplant; 1994; 13(4):571-82. PubMed ID: 7947873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mycophenolic acid: a welcome adjunct immunosuppressant after organ transplants].
    van Gelder T; Gregoor PJ; Hené RJ; De Sévaux RG; Hilbrands LB
    Ned Tijdschr Geneeskd; 1998 Jul; 142(27):1550-4. PubMed ID: 9763828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.